5 June 2020 - The treatment is intended for adult patients with diffuse large-cell B-cell lymphomas who relapse or do not respond to treatment and who are not eligible for blood stem cell transplantation.

The incremental treatment effect of Polivy in combination with bendamustine and rituximab in relation to the comparison options, was very difficult to estimate. 

TLV conducted scenario analyses to show how the cost per quality adjusted life year is affected when, among other things, the relative effect is varied. When Polivy is only available in a 140 mg package, TLV estimated that the cost per quality adjusted life year for Polivy in combination with bendamustine and rituximab is between SEK 830,000 and 1,650,000 compared to bendamustine and rituximab. 

When packaging of 30 mg becomes available, this estimate drops to between SEK 620,000 and SEK 1,230,000 per quality adjusted life year.

Read TLV News [Swedish]